aTyr Pharma (ATYR) Projected to Post Earnings on Wednesday

Key Points

• aTyr Pharma is expected to report Q1 2026 results before the market opens on Wednesday, May 6, with analysts projecting ($0.16) EPS; the company will host a results call on Friday, May 8 at 4:00 PM ET and last quarter reported ($0.14) EPS, beating estimates by $0.04.
• ATYR shares traded around $0.79 with a market cap of $77.81 million and a 12‑month range of $0.64–$7.29, while analysts’ consensus is an average rating of "Hold" (1 Buy, 5 Hold, 1 Sell) and an average price target of $25.67.
• Institutional investors own about 61.72% of the company, with major funds such as Vanguard, UBS, Octagon, Geode and Millennium recently increasing their positions.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 8, 2026 at 4:00 PM ET.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.04. On average, analysts expect aTyr Pharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

aTyr Pharma Trading Up 0.3%

ATYR stock opened at $0.79 on Wednesday. aTyr Pharma has a 12 month low of $0.64 and a 12 month high of $7.29. The company has a 50-day moving average price of $0.87 and a 200 day moving average price of $0.83. The stock has a market cap of $77.81 million, a PE ratio of -1.00 and a beta of 0.64.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ATYR shares. Jefferies Financial Group reaffirmed a "buy" rating on shares of aTyr Pharma in a research note on Friday, March 6th. Wall Street Zen raised shares of aTyr Pharma from a "sell" rating to a "hold" rating in a research note on Sunday, March 15th. One equities research analyst has rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, aTyr Pharma has an average rating of "Hold" and an average price target of $25.67.

Institutional Investors Weigh In On aTyr Pharma

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of aTyr Pharma by 21.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,630,935 shares of the company's stock worth $4,060,000 after purchasing an additional 975,887 shares during the period. UBS Group AG lifted its position in shares of aTyr Pharma by 158.1% in the 3rd quarter. UBS Group AG now owns 4,505,955 shares of the company's stock worth $3,249,000 after purchasing an additional 2,760,238 shares during the period. Octagon Capital Advisors LP lifted its position in shares of aTyr Pharma by 7.5% in the 2nd quarter. Octagon Capital Advisors LP now owns 3,820,000 shares of the company's stock worth $19,367,000 after purchasing an additional 268,000 shares during the period. Geode Capital Management LLC lifted its position in shares of aTyr Pharma by 4.8% in the 4th quarter. Geode Capital Management LLC now owns 2,283,717 shares of the company's stock worth $1,789,000 after purchasing an additional 105,514 shares during the period. Finally, Millennium Management LLC lifted its position in shares of aTyr Pharma by 22.0% in the 3rd quarter. Millennium Management LLC now owns 1,890,921 shares of the company's stock worth $1,364,000 after purchasing an additional 340,721 shares during the period. Hedge funds and other institutional investors own 61.72% of the company's stock.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company's research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.